跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 125 条关于
“NVAMD”
全部
125
临床试验
111
药物
0
机构
0
资讯
14
5个月前
Merck Initiates Pivotal Phase 2b/3 Trial for Novel Bispecific Antibody MK-8748 in Wet Age-Related Macular Degeneration
2年前
MSD Completes $3 Billion Acquisition of EyeBio, Gaining Novel Retinal Disease Candidate Restoret
4年前
Real-World Study Shows Faricimab Improves Outcomes in nAMD Patients
2年前
Switching to Ranibizumab Biosimilar Maintains Vision in nAMD Patients
去年
Aflibercept Biosimilar P041 Shows Comparable Efficacy and Safety to Eylea in nAMD
去年
Aflibercept 8 mg Shows Extended Dosing Intervals in Real-World nAMD Treatment
2年前
Faricimab Demonstrates Visual Stability and Extended Treatment Intervals in nAMD
去年
Sozinibercept Shows Promise in Improving Visual Outcomes for nAMD Patients
2年前
Real-World Data Highlights Faricimab's Effectiveness in Wet AMD and DME
去年
OPTIMAB® Biosimilar Demonstrates Non-Inferiority to Ranibizumab in nAMD Treatment
第 1 页,共 2 页
上一页
下一页